The effect of combined neurolytic blocking agent 5% phenol-glycerol in rat sciatic nerve.
Combined 5% phenol-glycerol has been used to treat cancer pain or spasticity and as sympathetic blocks. The major clinical problems have been the unpredictable effects on pain and on the duration of the blocks. Previously we have shown that intraneurally injected phenol induces haemorrhagic necrosis as well as dissolving of the nerve fibres. Glycerol, on the other hand, induces dispersion of nerve fibre debris into the endoneurium. We have now studied the effects of a combination of these two chemically different agents. The endoneurial and epineurial responses of rat peripheral nerve were followed after intraneural and perineural injections. Samples for electron microscopic and immunohistochemical studies were taken at 1-26 weeks after the injection. The intraneural phenol-glycerol injection resulted in gross endoneurial damage with partly or totally dissolved nerve fibres. Totally dissolved nerve fibres showed empty, collapsed basal lamina tubes and partly dissolved nerve fibres showed breaching of remaining degenerative debris into the endoneurial space. Axonal regeneration was delayed and was observed first after 2 weeks and it took 4 months before most of the nerve fibres were myelinated. The perineural injections resulted in partial subperineurial damage of the endoneurium morphologically similar to the results caused by the intraneural injection. An initial high accumulation of epineurial macrophages was noted at 1 and 2 weeks. An invasion of macrophages into the endoneurium occurred within 1 week after the intraneural and perineural injections and the number of endoneurial macrophages remained high for up to 6 months. The present study shows that glycerol added to phenol diminishes the necrotizing effect of phenol after an intraneural injection. Combined phenol-glycerol-induced nerve injury is reversible and the axons regenerate but residual morphological changes can be observed even after 6 months.
Westerlund
Taina
T
Department of Anaesthesiology, Loimaa District Hospital, 32200 Loimaa, Finland.
Vuorinen
Ville
V
Röyttä
Matias
M
D000818:Animals; D001369:Axons / Q000378:metabolism / Q000648:ultrastructure; D002452:Cell Count / Q000379:methods; D003451:Cryoprotective Agents / Q000494:pharmacology; D004202:Disinfectants / Q000494:pharmacology*; D004338:Drug Combinations; D053331:Ectodysplasins; D005990:Glycerol / Q000494:pharmacology*; D007091:Image Processing, Computer-Assisted / Q000379:methods; D007150:Immunohistochemistry / Q000379:methods; D015552:Injections, Intralesional / Q000379:methods; D008264:Macrophages / Q000378:metabolism / Q000648:ultrastructure; D008297:Male; D008565:Membrane Proteins / Q000378:metabolism; D008854:Microscopy, Electron / Q000379:methods; D009416:Nerve Regeneration / Q000187:drug effects; D016900:Neurofilament Proteins / Q000378:metabolism; D019800:Phenol / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D009418:S100 Proteins / Q000378:metabolism; D012583:Schwann Cells / Q000378:metabolism / Q000648:ultrastructure; D012584:Sciatic Nerve / Q000187:drug effects* / Q000473:pathology / Q000648:ultrastructure; D013997:Time Factors
D003451:Cryoprotective Agents; D004202:Disinfectants; D004338:Drug Combinations; D053331:Ectodysplasins; D008565:Membrane Proteins; C098235:NF70 protein, Helix aspersa; D016900:Neurofilament Proteins; D009418:S100 Proteins; C051774:neurofilament protein H; D019800:Phenol; D005990:Glycerol